Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome
| Autor: | Darijus Skaudickas, Povilas Aniulis, Mindaugas Jievaltas, Titas Telksnys, Vincentas Veikutis |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pelvic pain syndrome
medicine.medical_specialty Extracorporeal shock wave therapy Visual analogue scale extracorporeal shock wave therapy 030232 urology & nephrology chronic non-bacterial prostatitis Prostatitis Disease urologic and male genital diseases chronic pelvic pain syndrome 03 medical and health sciences 0302 clinical medicine Internal medicine medicine shock waves business.industry Mean age General Medicine medicine.disease female genital diseases and pregnancy complications Clinical trial 030220 oncology & carcinogenesis Medicine International Prostate Symptom Score business Research Article |
| Zdroj: | Open Medicine, Warsaw : De Gruyter, 2020, vol. 15, no. 1, p. 580-585 Open Medicine, Vol 15, Iss 1, Pp 580-585 (2020) Open Medicine |
| ISSN: | 2391-5463 |
| Popis: | Background Prostatitis is the most commonly diagnosed disease in men younger than 50 years and accounts for about 8% of all urologists’ consultations. Objective After evaluating clinical trials and demonstrating the efficacy of chronic non-bacterial prostatitis treatment, it remains of clinical importance to continue studies on the use of low-energy extracorporeal shock wave therapy (ESWT) in men. Materials and methods From May 2017 to April 2018, 40 patients with chronic prostatitis (CP) type IIIB/chronic pelvic pain syndrome (CPPS) were enrolled in the study. The patients underwent ESWT once a week for 4 weeks. Results The mean age of the patients was 47.8 years. A statistically significant improvement in all the parameters, i.e., the International Prostate Symptom Score (IPSS), the visual analogue scale (VAS), National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and the International Index of Erectile Function (IIEF), was observed at week 4. The effect of the treatment was maintained during the entire 12-week period. The NIH-CPSI total score showed the best improvement at week 4, but a slight deterioration without a statistically significant change was noticed at week 12. The greatest improvement at week 4 was documented for the NIH-CPSI and IPSS (43% and 37%, respectively). At week 12, an improvement of 52% and 39% was recorded for VAS and IPSS, respectively. Conclusions Our findings confirmed the effectiveness and safety of ESWT in resistant cases of CPPS in the short term. ESWT is cost-effective, which takes little time or requires a small amount of staff, and is easily conducted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|